SRR1394755
GTEX
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- GTEX
- cancer_type_detailed
- —
- subtype
- —
- cancer_type
- GTEX
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYOGENESIS+0.424
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.397
- TNFA_SIGNALING_VIA_NFKB+0.374
- CHOLESTEROL_HOMEOSTASIS+0.357
- KRAS_SIGNALING_DN+0.343
- APICAL_SURFACE+0.308
- APOPTOSIS+0.235
- FATTY_ACID_METABOLISM+0.234
- XENOBIOTIC_METABOLISM+0.231
- PANCREAS_BETA_CELLS+0.227
Top 10 suppressed
- G2M_CHECKPOINT-0.496
- MYC_TARGETS_V1-0.475
- E2F_TARGETS-0.462
- DNA_REPAIR-0.379
- MITOTIC_SPINDLE-0.322
- PROTEIN_SECRETION-0.309
- MYC_TARGETS_V2-0.269
- UNFOLDED_PROTEIN_RESPONSE-0.265
- PI3K_AKT_MTOR_SIGNALING-0.222
- TGF_BETA_SIGNALING-0.215
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR1409305 | GTEX | — | 0.877 |
| 2 | SRR1383059 | GTEX | — | 0.870 |
| 3 | SRR1413562 | GTEX | — | 0.868 |
| 4 | SRR1475909 | GTEX | — | 0.863 |
| 5 | SRR1405485 | GTEX | — | 0.862 |
| 6 | SRR1096851 | GTEX | — | 0.849 |
| 7 | SRR1341387 | GTEX | — | 0.847 |
| 8 | SRR1359171 | GTEX | — | 0.843 |
| 9 | SRR659013 | GTEX | — | 0.842 |
| 10 | SRR1391639 | GTEX | — | 0.839 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 29 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYOGENESIS | 0.424 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.397 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.374 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.357 | Remibrutinib | — uncovered |
| KRAS_SIGNALING_DN | 0.343 | Remibrutinib | — uncovered |
| APICAL_SURFACE | 0.308 | Temsirolimus | — uncovered |
| APOPTOSIS | 0.235 | Idelalisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.234 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.231 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.227 | Cobimetinib | — uncovered |
| BILE_ACID_METABOLISM | 0.212 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.212 | Inavolisib | — uncovered |
| HYPOXIA | 0.206 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.195 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.171 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.154 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.123 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.114 | Idelalisib | — uncovered |
| ADIPOGENESIS | 0.109 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.105 | Remibrutinib | — uncovered |